Clinical trials: Hepatic Tumor Resection
Hepatocellular Carcinoma, Postoperative Infection
Postoperative Antimicrobial Prophylaxis Versus Placebo for Infection Prevention in HCC After Liver Resection
This trial is a multi-center, double-blinded, randomized (1:1) clinical trial. The aim is to compare the postoperative infection rate between the 3 days postoperative AMP group and the placebo group in HCC patients undergoing…
- Trial name
- HCC (NCT03990974)
- Testing
- postoperative antimicrobial prophylaxis, No postoperative antimicrobial prophylaxis
- Where
- China
- Volunteers
- 458 people
- Sponsor
- Sun Yat-sen University
Hepatic Metastases, Colorectal Cancer
Resection of Colorectal Liver Metastases With or Without Routine Hilar Lymphadenectomy
It is uncertain, whether hilar lymphadenectomy should be performed routinely in patients undergoing resection of colorectal liver metastases.
- Trial name
- RELY (NCT01073358)
- Testing
- Routine hilar lymphadenectomy
- Where
- Germany
- Volunteers
- 166 people
- Sponsor
- Heidelberg University
Hepatocellular Carcinoma
Adjuvant Therapy With Anlotinib for HCC
Patients with high risk of disease recurrence after curative resection for hepatocellular carcinoma (HCC) deserve active intervention. However, there's limited treatment choice for these patients.
- Trial name
- NCT04947371
- Testing
- Anlotinib Hydrochloride
- Where
- China
- Sponsor
- Shanghai Zhongshan Hospital
Liver Cancer, Hepatocellular Carcinoma
Effect of a Perioperative Oral Nutritional Supplementation on Patients Undergoing Hepatic Surgery for Liver Cancer
Cirrhotic patients undergoing hepatic resection have a mortality rate near 10%, and 30 to 70% of them develop severe complications. These failures are mainly due to hepatic insufficiency.
- Conditions
- Liver Cancer, Hepatocellular Carcinoma, Cirrhosis, Liver Fibrosis
- Trial name
- IMPACT (NCT00151671)
- Testing
- Oral Impact®
- Where
- France
- Volunteers
- 35 people
- Sponsor
- Rennes University Hospital
Liver Tumors
Communicating Veins Between Adjacent Hepatic Veins: an Intra-operative Ultrasound Study
The search for communicating veins (CVs) between adjacent hepatic veins (HVs) has drawn its rationale from living donor liver transplantation (LDLT).
- Trial name
- NCT00960609
- Testing
- Ultrasound guided liver resection
- Where
- Italy
- Sponsor
- University of Milan
Hepatocellular Carcinoma
Hepatectomy Versus Radiofrequency Ablation for Hepatocellular Carcinoma Adjacent to Major Blood Vessels
This study will compare and analyze the difference between hepatectomy at deep and complex sites(adjacent to major blood vessels) of patients with HCC and PRFA prognosis, recovery after treatment as well as incidence of…
- Trial name
- NCT00814242
- Testing
- surgical resection, percutaneous radiationfrequency ablation
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Eastern Hepatobiliary Surgery Hospital
Resectable Hepatocellular Carcinoma Beyond Milan Criteria
Hepatectomy Versus Chemoembolization for Resectable Hepatocellular Carcinoma Beyond Milan Criteria
The purpose of this study is to compare the survival outcomes between hepatic resection and transarterial lipiodol chemoembolization (TACE) used as the initial treatment in patients with Resectable Hepatocellular Carcinoma Beyond…
- Trial name
- NCT02138981
- Testing
- Chemoembolization and Response-Dependent Resection, Immediate Resection
- Where
- China
- Volunteers
- 436 people
- Sponsor
- Sun Yat-sen University
Carcinoma, Hepatocellular, Liver Dysfunction
Evaluation of Remnant Liver Function Using Primovist-enhanced MRI Before Resection/Ablation of Hepatocellular Carcinoma
The purpose of this study is to determine whether the global and segmental hepatic uptake and excretion of Gd-EOB-DTPA on Gd-EOB-DTPA-enhanced liver MRI correlates with standard liver function test results in the patients with…
- Trial name
- LiFE (NCT01490203)
- Testing
- Gd-EOB-DTPA, MRI
- Where
- 4 sites in South Korea
- Volunteers
- 71 people, healthy volunteers welcome
- Sponsor
- Seoul National University Hospital
Hepatocellular Carcinoma
Nivolumab and Yttrium-90 in Treating Patients With Liver Cancer Undergoing Surgical Resection
This early phase I trial studies how well nivolumab and yttrium-90 work in treating patients with liver cancer who are undergoing surgical resection.
- Trial name
- NCT03812562
- Testing
- Nivolumab, Yttrium Y 90 Glass Microspheres
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Northwestern University
Localized Resectable Adult Primary Liver Cancer, Stage III Childhood Liver Cancer
Surgery With or Without Hepatic Arterial Chemotherapy in Treating Patients With Liver Cancer
RATIONALE: Drugs used in chemotherapy, such as fluorouracil and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00238160
- Testing
- cisplatin, fluorouracil, adjuvant therapy
- Where
- 4 sites in Japan
- Sponsor
- Kyoto University
Hepatocellular Carcinoma (HCC)
SBRT Versus Surgical Resection for Small HCC
Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related incidence and mortality in China and represents a major public health challenge.
- Trial name
- NCT07381660
- Testing
- Stereotactic body radiotherapy (SBRT), Resection
- Where
- China
- Volunteers
- 390 people
- Sponsor
- Sun Yat-sen University
HCC, Liver Cirrhosis
SALT for Liver Cirrhosis With HCC
HCC is the third leading cause of cancer deaths worldwide. Although surgical treatment may be effective in patients with HCC, the five-year survival rate is only 50-70%.
- Trial name
- NCT06069947
- Testing
- sequential adult left lateral lobe liver transplantation (SALT)
- Volunteers
- 40 people
- Sponsor
- RenJi Hospital
Adrenocortical Carcinoma, Breast Cancer
Tumor Necrosis Factor in Patients Undergoing Surgery for Primary Cancer or Metastatic Cancer
RATIONALE: Biological therapies, such as tumor necrosis factor, may stimulate the immune system in different ways and stop tumor cells from growing.
- Conditions
- Adrenocortical Carcinoma, Breast Cancer, Colorectal Cancer, Gastrointestinal Cancer
- Trial name
- NCT00436410
- Testing
- colloidal gold-bound tumor necrosis factor, electron microscopy, pharmacological study
- Where
- 2 sites in United States
- Volunteers
- 108 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Hepatocellular Carcinoma
TACE/HAIC Combined With Lenvatinib and Sintilimab in Neoadjuvant Therapy for Intermediate-stage HCC
The purpose of the study is to observe the effect of TACE/HAIC combined with lenvatinib and sintilimab as a neoadjuvant therapy before liver resection in preventing the recurrence in high-risk patients with hepatocellular…
- Trial name
- NCT05250843
- Testing
- TACE/HAIC, Lenvatinib, Sintilimab
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Third Affiliated Hospital, Sun Yat-Sen University
Hepatocellular Carcinoma
Long-term Outcomes of Ablation, Liver Resection, and Liver Transplant as First-line Treatment for Solitary HCC of 3 cm or Less
Curative-intent therapies for hepatocellular carcinoma (HCC) include radiofrequency ablation (RFA), liver resection (LR), and liver transplantation (LT). Controversy exists in treatment selection for early-stage tumors.
- Trial name
- NCT05193253
- Testing
- Radiofrequency ablation, Liver resection, Liver transplantation
- Volunteers
- 119 people
- Sponsor
- University Health Network, Toronto
Colorectal Cancer, Metastatic Cancer
Flt3L in Treating Patients With Metastatic Colorectal Cancer
RATIONALE: Flt3L may stimulate a person's immune system and help kill tumor cells. PURPOSE: Phase I trial to study the effectiveness of flt3L given to patients before undergoing surgery to remove metastases from colorectal cancer.
- Trial name
- NCT00003431
- Testing
- recombinant flt3 ligand
- Where
- United States
- Sponsor
- Duke University
Liver Cancer, Hepatocellular Carcinoma
I-FIGS Feasibility Study
Background: Removal of part of the liver (resection) is performed as a treatment for some cancers in the liver. To achieve the best possible outcomes, it is important that the cancer is removed completely (R0 resection) (1).
- Conditions
- Liver Cancer, Hepatocellular Carcinoma, Liver Metastasis Colon Cancer
- Trial name
- I-FIGS (NCT05616039)
- Testing
- Standard Liver Surgery, Indocyanine Fluorescent Image Guided Surgery (I-FIGS)
- Where
- United Kingdom
- Volunteers
- 42 people
- Sponsor
- University Hospital Plymouth NHS Trust
Ischemic Reperfusion Injury, Insufficiency; Hepatic, Postoperative
Methylprednisolone N Acetylcysteine in Hepatic Resections
This is a prospective double-blind randomized phase II clinical trial, with two groups of intervention (one with administration of N-acetylcysteine and the other with administration of methylprednisolone), and one group of…
- Conditions
- Ischemic Reperfusion Injury, Insufficiency; Hepatic, Postoperative, Liver Tumour
- Trial name
- MENHIR (NCT01726465)
- Testing
- Methylprednisolone, N-acetylcysteine
- Where
- Italy
- Volunteers
- 50 people
- Sponsor
- Istituto Clinico Humanitas
Intrahepatic Cholangiocarcinoma
A Study of Cisplatin or Carboplatin With Gemcitabine Versus Gemcitabine Alone as Adjuvant Therapy in Patients With Resected or Ablation Intra-Hepatic Cholangiocarcinoma
Compare the efficacy of adjuvant chemotherapy with Cisplatin or Carboplatin and Gemcitabine versus Gemcitabine in patients with resected or ablated intra-hepatic cholangiocarcinoma.
- Trial name
- NCT03081039
- Testing
- Carboplatin, Cisplatin, Gemcitabine
- Where
- United States
- Sponsor
- University of Louisville
Hepatic Metastases, Colon Cancer
Hepatic Arterial Infusion With Floxuridine and Dexamethasone Combination With Chemotherapy With/Without Bevacizumab for Hepatic Metastases From Colorectal Cancer
The purpose of this study is to determine whether the addition of bevacizumab, to hepatic arterial therapy with floxuridine (FUDR) and dexamethasone (Dex) (regional chemotherapy), and either oxaliplatin or CPT-11, plus…
- Conditions
- Hepatic Metastases, Colon Cancer, Rectal Cancer
- Trial name
- NCT00200200
- Testing
- Bevacizumab HAI plus systemic chemotherapy, HAI plus systemic chemotherapy
- Where
- 5 sites in United States
- Volunteers
- 73 people
- Sponsor
- Memorial Sloan Kettering Cancer Center